Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).

ABSTRACT:

Background

Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC.

Methods

Patients with PROC were randomised (2 : 1) to chemotherapy (weekly paclitaxel 80 mg m^-2 or four weekly pegylated liposomal doxorubicin 40 mg m^-2) or tamoxifen 40 mg daily. The primary end point was HRQoL. Secondary end points were PFS by RECIST and overall survival (OS).

Results

Between March 2002 and December 2007, 156 and 82 patients were randomised to chemotherapy and tamoxifen, respectively. In the chemotherapy arm, a significantly larger proportion of patients experience

SUBMITTER: Lindemann K 

PROVIDER: S-EPMC5318972 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature